Primary Biliary Cholangitis (PBC)
3
Pipeline Programs
2
Companies
2
Clinical Trials
1 recruiting
1
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
1
1
Early DiscoveryClinical DevelopmentMarket
On Market (1)
Approved therapies currently available
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2023
2024
2025
2026
2027
2028
2029
IpsenElafibranor
Parvus TherapeuticsPVT201
Clinical Trials (2)
Total enrollment: 276 patients across 2 trials
A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis
Start: Aug 2023Est. completion: May 2029276 patients
Phase 3Recruiting
Single Ascending Dose Study to Evaluate Safety Tolerability, Pharmacokinetics, and Pharmacodynamics of PVT201 in Healthy Subjects and Patients (PBC/PSC)
Start: Oct 2024Est. completion: Apr 2025
Phase 1Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 276 patients
2 companies competing in this space